20-F: Cardiol Therapeutics Enters License Agreement with Meros Polymers for Cannabinoid Delivery Technology

Cardiol Therapeutics secures an exclusive worldwide license from Meros Polymers for their cannabinoid delivery technology, aiming to develop novel therapies for cardiovascular and cardiopulmonary diseases.

Summary

• Cardiol Therapeutics has entered into a license agreement with Meros Polymers, gaining exclusive worldwide rights to Meros' cannabinoid delivery technology within a specified Field of Use.
• The agreement involves milestone payments from Cardiol to Meros, including $100,000 upon enrolling the first patient in a Phase IIB clinical trial and $500,000 upon enrolling the first patient in a Phase III clinical trial.
• A further $1,000,000 is payable upon receiving Regulatory Approval from the US FDA for any one of the Project Products.
• Cardiol will pay Meros royalties of 5% of worldwide Net Sales of Project Product and Meros Technology that it receives in relation to the human and animal disease indications and derivatives thereof described in part (a) of the Field of Use pursuant to this Agreement.
• Cardiol will pay to Meros 7% of any Non-Royalty Sub-License Income that Cardiol receives in relation to the human and animal disease indications and derivatives thereof described in part (a) of the Field of Use.
• Cardiol will pay to Meros royalties of 3.70% of worldwide Net Sales of Project Products and Meros Technology that it receives in relation to human and animal cardiovascular and/or cardiopulmonary disease, heart failure and /or cardiac arrhythmias diagnosis and/or treatments using the drugs mentioned in part (b) of the Field of Use pursuant to this Agreement.
• Cardiol will pay to Meros 5% of any Non-Royalty Sub-License Income that Cardiol receives in relation to any human and animal heart disease, heart failure and/or arrythmias indications as described in part (b) of the Field of Use and 4.1.3 above.
• Meros will receive 10% of Cardiol's issued and outstanding voting share capital, with half of those shares held in escrow until a specific milestone is achieved.
• A Meros nominee will be appointed to Cardiol's Board of Directors upon Cardiol securing $1,000,000 in financing.
• Cardiol is responsible for the costs of filing, prosecuting, and maintaining patents for Meros IP and Improvements.
• The agreement outlines terms for handling confidential information, intellectual property rights, and potential disputes.
• Cardiol must raise a minimum of $400,000 CAD by June 30, 2017, to support the Project Plan.

Sentiment

Score: 7

Explanation: The document outlines a potentially beneficial agreement for Cardiol, providing access to new technology and expertise. However, it also involves financial obligations and risks, resulting in a moderately positive sentiment.

Positives

• Cardiol gains access to a potentially valuable drug delivery technology.
• The exclusive license provides a competitive advantage in the development of cannabinoid-based therapies.
• The agreement includes provisions for collaboration and support from Meros.
• Meros will have a nominee on Cardiol's Board of Directors, providing Meros with influence over Cardiol's strategic decisions.

Negatives

• Cardiol is obligated to make significant milestone payments and royalty payments to Meros.
• The agreement requires Cardiol to raise a minimum of $400,000 CAD by June 30, 2017, which may be challenging.
• Cardiol is responsible for the costs of filing, prosecuting, and maintaining patents for Meros IP and Improvements.
• Cardiol's royalty payment obligations under this Agreement will expire on a product-by-product and country-by-country basis upon the expiration of the last to expire of a Valid Claim of the Meros Patent Rights that, but for the rights licensed under this Agreement, would be infringed by the manufacture, Development, use or sale of such product in such country.

Risks

• The success of the collaboration depends on the ability of Cardiol to successfully develop and commercialize products using the licensed technology.
• The agreement could be terminated if Cardiol fails to meet its obligations, including milestone payments and royalty payments.
• The value of the licensed technology may be diminished if Cardiol is unable to obtain and maintain patent protection.
• The agreement is governed by the laws of Alberta, which may be unfamiliar to Cardiol.

Future Outlook

Cardiol aims to develop and commercialize Project Products incorporating Meros Technology within the Field of Use, seeking regulatory approvals in the United States, Canada, and the European Union.

Management Comments

• Cardiol will consult with the Chief Scientific Officer of Meros before adjusting any formulation covered under the Meros Technology.

Industry Context

This agreement reflects a trend in the pharmaceutical industry towards collaborations and licensing agreements to leverage specialized technologies and expertise for drug development.

Comparison to Industry Standards

• Licensing agreements in the pharmaceutical industry often involve upfront payments, milestone payments, and royalties.
• The specific terms of this agreement, including the royalty rates and milestone payments, are comparable to industry standards for similar licensing agreements.
• The equity consideration granted to Meros is a less common feature, but it aligns the interests of both companies in the success of the collaboration.

Stakeholder Impact

• Shareholders: Potential for increased value through successful development and commercialization of new therapies.
• Employees: Potential for new job opportunities and career advancement.
• Patients: Potential for access to new and improved treatments for cardiovascular and cardiopulmonary diseases.
• Suppliers: Potential for increased business through the supply of materials and services for drug development and manufacturing.
• Creditors: Potential for increased financial stability and ability to repay debts.

Next Steps

• Cardiol to finalize the Project Plan within 150 days of the Commencement Date.
• Cardiol to seek Regulatory Approvals in relation to the Project Products within the United States, Canada, European Union and such other jurisdictions within the Territory as Cardiol may determine.
• Cardiol to make milestone payments upon achieving clinical trial milestones and FDA approval.

Key Dates

Keywords

Cardiol Therapeutics, Meros Polymers, License Agreement, Cannabinoids, Drug Delivery, Cardiovascular Disease, Pharmaceutical, Technology